31
Pharmacogenetics & Pharmacogenomics By M.H.Farjoo M.D. , Ph.D. Shahid Beheshti University of Medical Science

Genetic in pharmacology (pharmacogenomic)

Embed Size (px)

DESCRIPTION

The underlined words are hyperlinks; please click on them to see the whole presentation.Please tell me what you think about my slides, you can write to: [email protected]

Citation preview

Page 1: Genetic in pharmacology (pharmacogenomic)

Pharmacogenetics&

Pharmacogenomics

By

M.H.Farjoo M.D. , Ph.D.Shahid Beheshti University of Medical Science

Page 2: Genetic in pharmacology (pharmacogenomic)

Patient’s responseto drug

Diagnosis

Interactions with

concomitant drugs

Dose

Compliance

Genetic differences among patients

Response to Medicine

Page 3: Genetic in pharmacology (pharmacogenomic)
Page 4: Genetic in pharmacology (pharmacogenomic)
Page 5: Genetic in pharmacology (pharmacogenomic)
Page 6: Genetic in pharmacology (pharmacogenomic)

Sources of Pharmacokinetic and Pharmacodynamic Variability

Drug Specific:Dose & Schedule

Dosage formMorphometric:Body SizeBody Composition

Genetics:

Environment:Drug-drug interactions

Drug-CAM interactionsDrug-formulation interactions

Drug-food constituent interactions

Physiologic:DiseaseHepatic FunctionRenal Function

Demographic:AgeRace/EthnicitySex

Variability

Page 7: Genetic in pharmacology (pharmacogenomic)

Non-Responders and Patients Experiencing

Severe Toxicity

All patients with same diagnosis

Responders and Patients not Experiencing

Severe Toxicity

Page 8: Genetic in pharmacology (pharmacogenomic)
Page 9: Genetic in pharmacology (pharmacogenomic)

Definition

people respond differently to medicines due to their genetic inheritance.

Pharmacogenetics: study of genetically determined interindividual differences in response to drugs

Pharmacogenomics: use of genome based techniques in drug development

Page 10: Genetic in pharmacology (pharmacogenomic)

The Goals

Medicines do not have the same effect on everyone.

Some people do not respond at all, while others experience severe side effects.

Genetic factors account for some of these differences.

Recent research has suggested that 85% of patient responses to a drug are due to genetic factors.

Page 11: Genetic in pharmacology (pharmacogenomic)

The Goals

Pharmacogenetic determines:

How genetic make-up affects a drug effect. what side effects are likely to occur. Whether patients get the right drugs at the right dose.

scientists are trying:

to identify which genotypes respond to particular medicines.

To “personalise” medicines so that each drug has the desired effect on each person who uses it.

Page 12: Genetic in pharmacology (pharmacogenomic)

The Goals

Personalized Medicine: The Right Drug for the Right Patient at the Right Time

Page 13: Genetic in pharmacology (pharmacogenomic)
Page 14: Genetic in pharmacology (pharmacogenomic)

Pharmacogenetics The human genome contains 3 billion nucleotides

and the genomes of any 2 individuals vary in 3 million of them.

It is no surprise, then, that individuals have different responses to the same medicine.

Differences in our genes can affect drug absorption, distribution, metabolism and excretion.

Page 15: Genetic in pharmacology (pharmacogenomic)

Single Nucleotide Polymorphisms (SNPs or snips)

SNPs involve variations in single base pairs

This may not cause a change in amino acid sequence of a protein

But it may cause changes in the levels of its transcription or translation which affects response to a drug.

The aim is to identify SNPs determining which parts of the genome are relevant to drug response and to adverse reactions.

Page 16: Genetic in pharmacology (pharmacogenomic)

Succinylcholine Succinylcholine is used in surgery and some

patients suffer from prolonged paralysis.

Succinylcholine is broken down by an enzyme (Pseudocholinesterase).

The gene which codes for this enzyme is polymorphic.

The affected patients had a gene which coded for a different enzyme not capable of normal breakdown of acetylcholine.

Page 17: Genetic in pharmacology (pharmacogenomic)

Lymphoblastic Leukaemia

Mercaptopurine is used to treat lymphoblastic leukaemia in children.

It is broken down by an enzyme whose level is controlled by a single gene.

Homozygous people produce either very high or very low quantities of the enzyme.

Heterozygous people produce intermediate quantities of the enzyme.

Page 18: Genetic in pharmacology (pharmacogenomic)

Lymphoblastic Leukaemia

Page 19: Genetic in pharmacology (pharmacogenomic)

Lymphoblastic Leukaemia

Normal doses of mercaptopurine in homozygous negative patients can cause myelosuppression

The level of the enzyme can be measured using a simple blood test

this was one of the first pharmacogenetic tests in clinical use.

Page 20: Genetic in pharmacology (pharmacogenomic)

Alzheimer’s disease Sufferers have variations in the presence of

apolipoprotein E.

These differences predict not only the onset of the disease but also give clues for the treatment.

A drug can be given which slows progression in patients who do not have 2 copies of the gene for this protein.

Page 21: Genetic in pharmacology (pharmacogenomic)

Asthma bronchodilators are used for asthma but not

everyone responds in the same way.

>50% of the variance in response is due to genetic difference.

The drug that acts on bronchial smooth muscle has a target protein.

Some patients make a variant of this protein and cannot benefit from this form of treatment.

Page 22: Genetic in pharmacology (pharmacogenomic)

Techniques

Microarrays and Proteomics are used to identify how an individual’s genotype affects their response to a drug.

A microarray is a ‘chip’ which contains an array of DNA or RNA sequences or proteins.

It determines the effect of a drug on gene expression or to identify target genes for drug activity (i.e. to ‘design’ drugs).

Page 23: Genetic in pharmacology (pharmacogenomic)
Page 24: Genetic in pharmacology (pharmacogenomic)
Page 25: Genetic in pharmacology (pharmacogenomic)
Page 26: Genetic in pharmacology (pharmacogenomic)
Page 27: Genetic in pharmacology (pharmacogenomic)

Techniques

Proteomics is the study of all the proteins being expressed in a cell at a given time.

It can be used to help to identify which proteins may be good targets for drugs.

Page 28: Genetic in pharmacology (pharmacogenomic)
Page 29: Genetic in pharmacology (pharmacogenomic)
Page 30: Genetic in pharmacology (pharmacogenomic)

SummaryIn English

Page 31: Genetic in pharmacology (pharmacogenomic)

Thank youAny question?